Development of Anti- Yersinia pestis Human Antibodies with Features Required for Diagnostic and Therapeutic Applications

• Published in: ImmunoTargets and therapy Vol. 9; pp. 299 - 316
• Main Authors: Lillo, Antonietta M, Velappan, Nileena, Kelliher, Julia M, Watts, Austin J, Merriman, Samuel P, Vuyisich, Grace, Lilley, Laura M, Coombs, Kent E, Mastren, Tara, Teshima, Munehiro, Stein, Benjamin W, Wagner, Gregory L, Iyer, Srinivas, Bradbury, Andrew R M, Harris, Jennifer Foster, Dichosa, Armand E, Kozimor, Stosh A
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 2020; Taylor & Francis Ltd; Dove Press; Dove; Dove Medical Press
• Subjects: 60 APPLIED LIFE SCIENCES; Agglutination; Antibiotics; Antibodies; Antigens; Bacteria; Cells (Biology); Drug resistance; Enzyme-linked immunosorbent assay; Epithelial cells; Flow cytometry; Health aspects; immunoantibiotic; immunodiagnostic; Immunoglobulin G; Immunoreactivity; immunotherapy; lateral flow assay; LFA; Mammalian cells; Mass spectrometry; Mass spectroscopy; Microbial drug resistance; Monoclonal antibodies; Multidrug resistance; Mutation; National security; Original Research; Phages; Plague; Proteins; Public health; radioimmunotherapy; radiolabeling; RIT; Scientific equipment industry; Therapeutic applications; Therapeutics; Virulence; Yersinia pestis; United States; Massachusetts; United States > US; radioimmunotherapy; lateral flow assay; LFA; immunotherapy; immunodiagnostic; radiolabeling; RIT; immunoantibiotic

is a category A infective agent that causes bubonic, septicemic, and pneumonic plague. Notably, the acquisition of antimicrobial or multidrug resistance through natural or purposed means qualifies as a potential biothreat agent. Therefore, high-quality antibodies designed for accurate and sensitive...